Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&amp;T

Derlin, Thorsten; Schmuck, Sebastian; Juhl, Cathleen; Teichert, Steffi; Zörgiebel, Johanna; Wester, Hans‐Jürgen; Schneefeld, Sophie; Walte, Almut; Thackeray, James T.; Roß, Tobias L.; Bengel, Frank M.

doi:10.1007/s11307-018-1160-8

Cited by 23 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five years after prostatectomy, the PSA reached 10.6 μg/L, and the patient underwent a [ 68 Ga]Ga-THP-PSMA PET/CT using a cold kit PSMA formulation [ 22 – 25 ]. Sixty minutes after intravenous injection of 204 MBq of tracer a [ 68 Ga]Ga-THP-PSMA PET/CT was acquired from proximal thighs to skull base on a GE Discovery 690 PET-CT scanner (GE Healthcare, Chicago, USA) according to current guidelines [ 5 ] (4 min per bed position with 23% overlap and axial field of view of 16 cm).…”

Section: Case Presentationmentioning

confidence: 99%

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

et al. 2020

View full text Add to dashboard Cite

Background Brain metastases from prostate cancer are rare and usually only occur in the context of widespread systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intact prostate cancer patient with no other systemic disease, detected using [68Ga]Ga-THP-PSMA PET/CT and only the second one using a PSMA-based radiopharmaceutical. Case presentation We report the case of a prostate cancer patient presenting 5 years after robot-assisted laparoscopic prostatectomy with biochemical recurrence, no neurological symptoms, and in the absence of metastatic lesions in the body on conventional imaging. A solitary cerebral metastasis was detected using [68Ga]Ga-THP-PSMA PET/CT, surgically resected, leading to a drop in serum PSA and a good recovery. Conclusion In this case, [68Ga]Ga-THP-PSMA PET/CT resulted in a major change in clinical management and avoided additional morbidity associated with delayed diagnosis and treatment. This report demonstrates the importance of considering the presence of metastatic disease outside the conventional locations of prostate cancer spread, as well as the importance of ensuring comprehensive [68Ga]Ga-PSMA PET/CT coverage from vertex to upper thighs.

show abstract

Section: Case Presentationmentioning

confidence: 99%

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The comparison of both tracers in patients revealed a higher sensitivity and therefore the slight superiority of 68 Ga-PSMA-11 [160]. Other 68 Ga-labelled compounds studied include [ 68 Ga]Ga-THP-PSMA [161] and [ 68 Ga]Ga-P16-093 [162]. Of advantage for [ 68 Ga]Ga-THP-PSMA might be the rapid production via a kit labelling procedure and the low tracer accumulation in the body.…”

Section: Prostate-specific Membrane Antigenmentioning

confidence: 99%

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Rangger

Haubner

2020

Pharmaceuticals

View full text Add to dashboard Cite

This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.

show abstract

“…Ga-68 PSMA PET/BT'de PSMA radyotraserının farklı türlerinden PSMA-HBED yaygın olarak kullanılan ve en çok bildirilen veriye sahip olmasına karşın, diğer türler PSMA I&T ve THP-PSMA'nında klinik kullanımda PSMA-HBED için iyi birer alternatif oldukları düşünülmektedir (65). Üretim sürecinin basitleştirilmesi veya "soğuk kit" şeklinde kullanılabilmesi nedeniyle THP-PSMA gibi ajanların kullanılabilirliği artacak gibi gözükmektedir (66). F-18 ile işaretli PSMA'ya erişimin artmasıyla az miktarda veri olmasına karşın ilk veriler ışığında Ga-68 PSMA'ya nazaran BKN durumunda metastazları daha iyi tespit edebileceğimiz anlaşılmaktadır (67).…”

Section: Hastalığınyönetimindekietkisiunclassified

Prostate-Specific Membrane Antigene PET/CT in Biochemical Recurrence

Elboğa¹

2018

nts

View full text Add to dashboard Cite

Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T

Cited by 23 publications

References 24 publications

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Prostate-Specific Membrane Antigene PET/CT in Biochemical Recurrence

Contact Info

Product

Resources

About